Nektar Therapeutics (NKTR)

NASDAQ
15.87
+0.25(+1.60%)
After Hours
16.08
+0.21(+1.32%)
- Real-time Data
  • Volume:
    731,829
  • Bid/Ask:
    15.91/16.09
  • Day's Range:
    15.55 - 15.95

NKTR Overview

Prev. Close
15.62
Day's Range
15.55-15.95
Revenue
125.99M
Open
15.74
52 wk Range
15.37-26.73
EPS
-2.39
Volume
731,829
Market Cap
2.85B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
893,060
P/E Ratio
-
Beta
1.45
1-Year Change
-27.03%
Shares Outstanding
182,308,999
Next Earnings Date
Aug 05, 2021
What is your sentiment on Nektar Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Nektar Therapeutics News

Nektar Therapeutics Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuySellSellStrong Sell
Technical IndicatorsBuyBuyBuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell

Nektar Therapeutics Company Profile

Nektar Therapeutics Company Profile

Employees
718

Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company’s products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.

Read More
  • They better do what they're supposed to, reach 31 :D
    0
    • ok
      0
  • That's a crappy stock bro. Don't be pushing that garbage in here!
    0
    • AMC and Koss
      2
      • why this gone down so much today any idea?
        0
        • TUSK double the price very soon..Very low volume.. Easy to jump.. Don't miss it.. Good luck guys..
          0
          • k
            0
        • PDUFA on the 14th. probably reason for run up
          1
          • Why going up?
            1
            • We should forget for longtime about this rubbish company.
              1
              • won't be rubbish when BMY buys them out.
                0
            • Why the current uptrend? Amlost 20% in twp days. Any news or just technicals?
              0
              • I think it goes down more tomorrow and jump up right after FDA say something promissing.
                0
                • It can go more down ?
                  1
                  • u never know. if u want it u can sell a put option at 16 or so for atleast 90day. any case u can also buy a put option below that to hedge in case it breaches down from there but try to buy a longer period put.
                    0
                • I thought I invested in Nektar not Niagara Falls lol
                  0
                  • keep the option buttons ready
                    0
                • buy!
                  1
                  • And... megaweak
                    0
                    • soo weak ..
                      0
                      • Explode soon
                        0
                        • Any chance to go up here?
                          1
                          • buy and hold for a months you will make money
                            0
                          • lol this guy probably lost everything he owned by now
                            0
                        • what happen here?
                          1
                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.